Go Pro
OTCMKTS:EDTXF

Spectral Diagnostics Q1 2025 Earnings Report

Spectral Diagnostics logo
$0.83 +0.02 (+2.94%)
As of 09/29/2026 09:54 AM Eastern

Spectral Diagnostics EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Spectral Diagnostics Revenue Results

Actual Revenue
$0.40 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spectral Diagnostics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Spectral Diagnostics' next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules.

Conference Call Resources

Spectral Diagnostics Earnings Headlines

Spectral Medical Inc EDTXF
Trump Wants to Reprice America's Gold at Market Value
The US government still values its gold reserves at 42 dollars an ounce, a price Congress set in 1973. Gold trades above 4000 today, leaving official books showing about 11 billion dollars for holdings worth more than 1 trillion in the real market. A bill now moving through Congress would require the Treasury to reprice that gold at current market value, while companion legislation could trigger the first audit of US gold holdings in more than 65 years. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free.tc pixel
See More Spectral Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Diagnostics and other key companies, straight to your email.

About Spectral Diagnostics

Spectral Diagnostics (OTCMKTS:EDTXF), now known as Spectral Medical Inc., is a Canadian medical-device and biotechnology company focused on products for the diagnosis and treatment of sepsis and septic shock. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and can contribute to severe systemic inflammation.

Spectral’s primary diagnostic product is the Endotoxin Activity Assay (EAA), a blood test designed to measure a patient’s endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis. The assay is intended to support physicians in assessing patients and selecting potential treatment strategies.

The company has also been involved in the development and commercialization of blood-purification therapies, including polymyxin B hemoperfusion, which is designed to remove endotoxins from the bloodstream. Spectral Medical serves the critical-care and hospital markets, with operations and commercial activities focused primarily in North America and other international markets through regulatory and distribution relationships.

View Spectral Diagnostics Profile